Coverage
-
August 22, 2019
Chiasma investors fought back Wednesday against a pair of objectors to the $18.7 million settlement of a shareholder suit against the biopharmaceutical company, arguing that they lack standing to appeal and should have to post an appeal bond.
3 other articles on this case.
View all »